Pfizer Stock News

FAA will reduce air traffic by 10% across 40 major markets due to staffing shortages from the government shutdown, impacting 3,500-4,000 flights daily. Pfizer (PFE) has matched Novo Nordisk's bid for obesity biotech Metsera (MTSR), valuing it at $10 billion, intensifying the takeover battle.

Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line.

Turnaround stocks often face a lot of negativity from investors until their turnaround efforts start bearing fruit. United Parcel Service is working to streamline its operations so it can become a more profitable business.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today issued the following statement in response to the Delaware Chancery Court's decision denying Pfizer's request for a temporary restraining order to prevent Metsera, Inc. from terminating the existing merger agreement in favor of a competing proposal from Novo Nordisk. “We remain confident in the merits of our claims and our belief that Met...

Pfizer is preparing to sweeten its offer again for Metsera , the Wall Street Journal reported on Wednesday, citing people familiar with the matter.

Pfizer is preparing to sweeten its offer again for Metsera, the weight-loss drug startup at the center of a bidding war that also involves Novo Nordisk.

A Delaware judge said on Wednesday she would reject a request by Pfizer to temporarily block Metsera from terminating its takeover deal with Pfizer, allowing Metsera to proceed instead with a higher $10 billion deal from Novo Nordisk.

Pfizer has removed some conditions in its bid for Metsera as it tries to overcome a rival $10 billion bid by Novo Nordisk for the obesity drug developer, the U.S. drug giant said in a letter to a Delaware judge on Wednesday.